R H Boger

Summary

Affiliation: University of Hamburg
Country: Germany

Publications

  1. ncbi A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria
    Latika Sibal
    Newcastle University, Newcastle upon Tyne, UK
    Cardiovasc Diabetol 8:27. 2009
  2. ncbi Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease
    R H Boger
    Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Intern Med 269:349-61. 2011
  3. ncbi Association of asymmetric dimethylarginine and endothelial dysfunction
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Chem Lab Med 41:1467-72. 2003
  4. ncbi ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Martinistr 2, D 20246 Hamburg, Germany
    Atheroscler Suppl 4:23-8. 2003
  5. ncbi Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-(15)N(2)]-arginine to (15)N-labeled nitrate by gas chromatography--mass spectrometry
    Rainer H Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Nitric Oxide 11:1-8. 2004
  6. ncbi Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital, Hamburg Eppendorf, Germany
    J Nutr 134:2842S-2847S; discussion 2853S. 2004
  7. ncbi L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Germany
    Altern Med Rev 10:14-23. 2005
  8. ncbi Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Chem Lab Med 43:1124-9. 2005
  9. ncbi Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
    Rainer H Boger
    Clinical Pharmacology Unit, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 10:S19-25. 2005
  10. ncbi ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
    Rainer H Boger
    Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 10:S97-102. 2005

Detail Information

Publications84

  1. ncbi A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria
    Latika Sibal
    Newcastle University, Newcastle upon Tyne, UK
    Cardiovasc Diabetol 8:27. 2009
    ..The aim of the present study was to measure circulating ADMA, and define its association with endothelial dysfunction and endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease...
  2. ncbi Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease
    R H Boger
    Institute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Intern Med 269:349-61. 2011
    ..Symmetric dimethylarginine (SDMA) does not inhibit NO synthases. Peripheral arterial disease (PAD) is a systemic indication of atherosclerosis...
  3. ncbi Association of asymmetric dimethylarginine and endothelial dysfunction
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Chem Lab Med 41:1467-72. 2003
    ..Recent prospective studies suggest that endothelial dysfunction indicates an increased risk of future cardiovascular events. In line with these observations, we and others found evidence that ADMA is a novel cardiovascular risk factor...
  4. ncbi ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Martinistr 2, D 20246 Hamburg, Germany
    Atheroscler Suppl 4:23-8. 2003
    ..As other researchers reported observations that are in line with our findings, there is evidence that ADMA may be a novel cardiovascular risk factor...
  5. ncbi Hypercholesterolemia impairs basal nitric oxide synthase turnover rate: a study investigating the conversion of L-[guanidino-(15)N(2)]-arginine to (15)N-labeled nitrate by gas chromatography--mass spectrometry
    Rainer H Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Nitric Oxide 11:1-8. 2004
    ....
  6. ncbi Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital, Hamburg Eppendorf, Germany
    J Nutr 134:2842S-2847S; discussion 2853S. 2004
    ..Finally, ADMA has gained clinical importance recently because several studies have shown that ADMA is an independent cardiovascular risk factor...
  7. ncbi L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Germany
    Altern Med Rev 10:14-23. 2005
    ..Supplementation with L-arginine has been shown to restore vascular function and to improve the clinical symptoms of various diseases associated with vascular dysfunction...
  8. ncbi Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Chem Lab Med 43:1124-9. 2005
    ..Recently, advances have been made in the development of analytical methods that are reliable and fast enough to allow determination of ADMA in clinical routine...
  9. ncbi Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials
    Rainer H Boger
    Clinical Pharmacology Unit, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 10:S19-25. 2005
    ..However, we need to define more clearly in the future who will profit from ADMA determination, in order to use this novel risk marker as a more specific diagnostic tool...
  10. ncbi ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
    Rainer H Boger
    Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 10:S97-102. 2005
    ....
  11. ncbi Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Ann Med 38:126-36. 2006
    ..Supplementation with L-arginine has been shown to restore vascular function and to improve the clinical symptoms of various diseases associated with vascular dysfunction...
  12. ncbi Renal impairment: a challenge for opioid treatment? The role of buprenorphine
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Martinistr 52, D 20246 Hamburg, Germany
    Palliat Med 20:s17-23. 2006
    ..Thus, in patients with reduced renal function, chronic renal insufficiency and haemodialysis, buprenorphine appears to be a safe choice when opioid treatment is initiated...
  13. ncbi Live and let die: asymmetric dimethylarginine and septic shock
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Crit Care 10:169. 2006
    ..A mechanism is proposed by which the interplay between ADMA and inducible NO synthase activity is mediated. ADMA levels should be determined in future studies evaluating the regulation of NO in the intensive care setting...
  14. ncbi The pharmacodynamics of L-arginine
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    J Nutr 137:1650S-1655S. 2007
    ..In conclusion, the effects of L-arginine supplementation on human physiology appear to be multicausal and dose-related. Doses of 3-8 g/d appear to be safe and not to cause acute pharmacologic effects in humans...
  15. ncbi L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Curr Opin Clin Nutr Metab Care 11:55-61. 2008
    ....
  16. ncbi The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, D 20246 Hamburg, Germany
    Cardiovasc Res 59:824-33. 2003
    ..Among other treatments, the administration of L-arginine has been shown to improve endothelium-dependent vascular function in subjects with high ADMA levels...
  17. ncbi [Drug therapy of coronary heart disease--are therapeutic guidelines being paid attention to?]
    G I Böger
    Arbeitsgruppe Klinische Pharmakologie, Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Universitatsklinikum Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Z Kardiol 92:466-75. 2003
    ..The present study shows that evidence-based guidelines for the drug treatment of coronary heart disease are not adequately put into practice...
  18. ncbi Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans
    R H Boger
    Institute of Clinical Pharmacology, Hannover Medical School, 30623 Hannover, Germany
    Clin Sci (Lond) 100:161-7. 2001
    ..This finding may have importance for understanding the mechanism(s) leading to homocyst(e)ine-associated vascular disease, and its potential treatment...
  19. ncbi Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk
    Rainer H Boger
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Germany
    Pharmacol Res 60:481-7. 2009
    ....
  20. ncbi Drug interactions of the statins and consequences for drug selection
    R H Boger
    Department of Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Int J Clin Pharmacol Ther 39:369-82. 2001
    ..Statins that are not metabolized by a single cytochrome P450 isoenzyme, and have a high bioavailability, are the least prone to drug interactions...
  21. ncbi Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
    R H Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany
    Arterioscler Thromb Vasc Biol 20:1557-64. 2000
    ..Because ADMA acts as a competitive inhibitor of endothelial nitric oxide synthase, these findings suggest a novel mechanism for impaired endothelial function in hyperhomocyst(e)inemia...
  22. ncbi Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy
    Jan Galle
    Department of Internal Medicine, University Hospital, Wurzburg, Germany
    Nephrol Dial Transplant 23:3174-83. 2008
    ..Experimental evidence demonstrates that angiotensin receptor blockers (ARBs) possess anti-inflammatory potential, which might contribute to reducing proteinuria and providing renoprotection...
  23. ncbi Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease
    J T Kielstein
    Institute of Clinical Pharmacology and Department of Nephrology, Hannover Medical School, 30625 Hannover, Germany
    Kidney Int Suppl 78:S9-13. 2001
    ..Clinical studies on the effect of ADMA are needed to further elucidate its pathophysiological role in atherosclerosis and uremia...
  24. ncbi Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
    R H Boger
    Institute of Clinical Pharmacology, Hannover Medical School, Germany
    J Am Coll Cardiol 32:1336-44. 1998
    ..Administration of L-arginine improves nitric oxide (NO) formation and endothelium-dependent vasodilation in atherosclerotic patients...
  25. ncbi Lovastatin maintains nitric oxide--but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery
    R P Brandes
    Division of Cardiology, Hannover Medical School, Germany
    Atherosclerosis 142:97-104. 1999
    ..Lovastatin selectively maintains nitric oxide-mediated endothelium-dependent relaxation in hypercholesterolemic rabbit carotid arteries...
  26. ncbi Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA
    Karsten Sydow
    Division of Cardiology, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 9:93-101. 2004
    ..e. treatment with ACE inhibitors and AT1-receptor blockers to reduce ADMA plasma concentrations or L-arginine, could be a beneficial tool for treating patients with hyperhomocysteinemia...
  27. ncbi Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension
    Milica Bajcetic
    Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology Unit, University Hospital Hamburg Eppendorf, Martinistrasse 521, D 20246 Hamburg
    J Clin Pharmacol 47:295-304. 2007
    ..Larger crossover trials will have to establish these observations and investigate whether interaction of both drugs affects telmisartan efficacy and tolerability in clinical use...
  28. ncbi Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis
    S M Bode-Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany
    J Investig Med 48:125-32. 2000
    ....
  29. ncbi Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects
    F Schulze
    University Hospital Hamburg Eppendorf, Centre for Experimental Medicine, Institute of Experimental and Clinical Pharmacology and Toxicology, Clinical Pharmacology Unit, Hamburg, Germany
    Eur J Clin Invest 35:622-6. 2005
    ..Asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of NO-synthase. In the last years ADMA has emerged as a cardiovascular risk factor. The aim of this study was to determine a reference value for ADMA...
  30. ncbi LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases
    R H Boger
    Institute of Clinical Pharmacology, Hannover Medical School, Germany
    Circ Res 87:99-105. 2000
    ..These findings suggest a novel mechanism by which ADMA concentration is elevated in hypercholesterolemia, leading to endothelial dysfunction and atherosclerosis...
  31. ncbi Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry
    D Tsikas
    Institute of Clinical Pharmacology, Hannover Medical School, Germany
    J Chromatogr B Biomed Sci Appl 742:143-53. 2000
    ..The assay described in this work allows for accurate, specific and highly sensitive determination of nitric oxide synthase activity in vitro and in vivo...
  32. ncbi Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases
    R H Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany
    Semin Thromb Hemost 26:539-45. 2000
    ..Moreover, it may be a marker or even a risk factor for cardiovascular disease. Therefore, pharmacological modulation of ADMA concentration may be a novel therapeutic target in cardiovascular diseases...
  33. ncbi Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease
    E Schwedhelm
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Thromb Haemost 8:2662-70. 2010
    ..We sought to investigate the prevalence of this phenomenon in patients with stable CHD and to study whether oxidative stress plays a role in its pathogenesis...
  34. ncbi Effects of carvedilol on oxidative stress in human endothelial cells and healthy volunteers
    Stefanie A Fahlbusch
    Institute of Clinical Pharmacology, Medizinische Hochschule Hannover, 30623 Hannover, Germany
    Eur J Clin Pharmacol 60:83-8. 2004
    ..CONCLUSIONS: In vitro, the antioxidative potential of carvedilol was confirmed. In healthy men, antihypertensive doses of carvedilol exert no specific inhibition of oxidative stress...
  35. ncbi Oral L-arginine improves endothelial function in healthy individuals older than 70 years
    Stefanie M Bode-Boger
    Institute of Clinical Pharmacology, University Hospital, Otto von Guericke University, Magdeburg, Germany
    Vasc Med 8:77-81. 2003
    ..05). We conclude that in healthy very old age endothelial function is impaired and may be improved by oral L-arginine supplementation, probably due to normalization of the L-arginine/ADMA ratio...
  36. ncbi Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity
    Chi Un Choe
    Department of Neurology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Neurochem 110:1766-73. 2009
    ..Taken together, our data indicate that HNO might worsen cerebral ischemia-reperfusion injury by increasing oxidative stress and decreasing brain perfusion at concentrations shown to be cardioprotective in vivo...
  37. ncbi Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox
    D Tsikas
    Institute of Clinical Pharmacology, Hannover Medical School, Carl Neuberg Strasse 1, D 30623, Hannover, Germany
    FEBS Lett 478:1-3. 2000
    ..In the present work, evidence for the hypothesis that the endogenous NOS inhibitors methylarginines, asymmetric dimethylarginine being the most powerful (IC(50) 1.5 microM), are responsible for the L-arginine paradox is presented...
  38. ncbi Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Regi
    Renke Maas
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Chem 53:693-701. 2007
    ..We investigated the association between plasma concentrations of ADMA and risk in initially healthy smoking and nonsmoking men...
  39. ncbi Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke
    Friedrich Schulze
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Atherosclerosis 208:518-23. 2010
    ..ADMA is a predictor of cardiovascular events and mortality in diverse populations...
  40. ncbi Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease
    Jan T Kielstein
    Department of Internal Medicine and Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
    J Am Soc Nephrol 13:170-6. 2002
    ..Thus, the early increase of ADMA levels may be of relevance for the excess cardiovascular morbidity and mortality due to arterio- and atherosclerotic complications in patients with renal disease...
  41. ncbi L-Arginine enhances the triglyceride-lowering effect of simvastatin in patients with elevated plasma triglycerides
    Friedrich Schulze
    Center for Experimental Medicine, Institute for Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Hamburg 20246, Germany
    Nutr Res 29:291-7. 2009
    ..We conclude from our data that L-arginine enhances the effects of simvastatin on lipid metabolism, but it has no triglyceride-lowering effects when given alone...
  42. ncbi Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding
    J T Kielstein
    Division of Nephrology, Hannover Medical School, Hannover, Germany
    Clin Nephrol 62:295-300. 2004
    ..Despite its low molecular weight, available information on the impact of hemodialysis (HD) on ADMA plasma levels is controversial...
  43. ncbi Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between ox
    Ralf A Benndorf
    Clinical Pharmacology Unit, Department of Pharmacology, University Hospital Hamburg, Hamburg, Germany
    Circ Res 103:1037-46. 2008
    ..By this mechanism, isoprostanes may contribute directly to exacerbation of coronary heart disease and to capillary rarefaction in disease states of increased oxidative stress...
  44. ncbi Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort
    Edzard Schwedhelm
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Chem 55:1539-45. 2009
    ..Relatively small differences in ADMA concentrations between healthy individuals and those with disease underscore the need to formulate reference intervals that may aid risk stratification of individuals...
  45. ncbi Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice
    Ralf A Benndorf
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Toxicology and Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Kidney Int 75:1039-49. 2009
    ..Whether activation of the AT2 receptor will have therapeutic benefit in chronic kidney disease will require further study...
  46. ncbi Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery
    Renke Maas
    University Hospital Hamburg Eppendorf, Institute of Experimental and Clinical Pharmacology and Toxicology, Hamburg, Germany
    Crit Care Med 35:1876-81. 2007
    ..We aimed to investigate elevated plasma ADMA concentrations as a prospective risk marker for adverse events in patients undergoing noncardiac surgery...
  47. ncbi Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism
    Edzard Schwedhelm
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Centre Hamburg Eppendorf, Germany
    Br J Clin Pharmacol 65:51-9. 2008
    ..In contrast, L-citrulline is readily absorbed and at least in part converted to L-arginine. The aim of our study was to assess this metabolic conversion and its subsequent pharmacodynamic effects...
  48. ncbi Acute effects of various fast-food meals on vascular function and cardiovascular disease risk markers: the Hamburg Burger Trial
    Tanja K Rudolph
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Am J Clin Nutr 86:334-40. 2007
    ..High-fat meals have negative effects on endothelial function, but vitamin-rich side orders may prevent these negative effects...
  49. ncbi Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease
    Sönke Arlt
    Department of Psychiatry and Psychotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Dement Geriatr Cogn Disord 26:58-64. 2008
    ..Concerning Alzheimer's disease (AD), there are reports on altered cerebral NO metabolism, but only few studies on ADMA concentrations in plasma and cerebrospinal fluid (CSF)...
  50. ncbi Telmisartan improves endothelial function in patients with essential hypertension
    Ralf A Benndorf
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Medical Center, Hamburg Eppendorf, Germany
    J Cardiovasc Pharmacol 50:367-71. 2007
    ..We therefore investigated whether the new ARB telmisartan improves endothelial function and renal vascular resistance in patients with essential hypertension...
  51. ncbi Simultaneous assessment of endothelial function, nitric oxide synthase activity, nitric oxide-mediated signaling, and oxidative stress in individuals with and without hypercholesterolemia
    Renke Maas
    Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Clin Chem 54:292-300. 2008
    ..It was the aim of this study to directly estimate and compare whole-body NO production in normo- and hypercholesterolemia by applying a nonradioactive stable isotope dilution technique in vivo...
  52. ncbi The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf Martinistrasse 52, DE 20246 Hamburg, Germany boeger uke uni hamburg de
    Gynecol Obstet Invest 69:1-13. 2010
    ..Recently, diagnostic assays for ADMA, e.g. by ELISA, have become available, which render ADMA a possible biomarker to identify pregnant women at risk of developing preeclampsia...
  53. ncbi Asymmetric dimethylarginine predicts outcome and time of stay in hospital in patients attending an internal medicine emergency room
    Friedrich Schulze
    University Hospital Hamburg Eppendorf, Institute for Experimental and Clinical Pharmacology and Toxicology, Hamburg, Germany
    Clin Chim Acta 401:20-4. 2009
    ..We investigated the predictive value of asymmetric dimethylarginine (ADMA) in unselected patients attending an internal medicine ER regarding outcome of the patients and duration of stay in the hospital...
  54. ncbi Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine
    Gerhild I Böger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Hamburg, Germany
    J Am Coll Cardiol 49:2274-82. 2007
    ..We hypothesized that the level of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide (NO) synthase (eNOS), might determine the endothelial effects of statins...
  55. ncbi A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue
    Renke Maas
    Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 851:220-8. 2007
    ..9% and 10% for mouse kidney and liver, respectively. The present DDAH activity assay allows for the first time to simultaneously determine DDAH activity and endogenous formation of ADMA, SDMA, and L-arginine in tissue...
  56. ncbi ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins
    Karsten Sydow
    Department of Cardiology, University Hospital Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Cardiovasc Res 57:244-52. 2003
    ..We investigated whether oral treatment with B vitamins or L-arginine normalizes endothelium-dependent, flow-dependent vasodilation (FDD) in patients with peripheral arterial occlusive disease (PAOD) and hyperhomocyst(e)inemia...
  57. ncbi Old and new cardiovascular risk factors: from unresolved issues to new opportunities
    Renke Maas
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Atheroscler Suppl 4:5-17. 2003
    ..With several new risk factors and substantial changes in lifestyle and treatment patterns on the horizon major changes in the hierarchy of risk factors may be inevitable...
  58. ncbi Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease
    Edzard Schwedhelm
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Clin Chem Lab Med 41:1552-61. 2003
    ..Results from several clinical studies are included indicating the validity of isoprostanes as surrogate parameters of oxidative stress in cardiovascular disease...
  59. ncbi Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study
    Edzard Schwedhelm
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Circulation 109:843-8. 2004
    ..We tested the hypothesis that risk factors of CHD are associated with abundant systemic oxidative stress...
  60. ncbi Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells
    Ralf Benndorf
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Circ Res 93:438-47. 2003
    ..These findings may explain the reported antiangiogenic properties of the AT2 receptor...
  61. ncbi Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay
    Friedrich Schulze
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center for Experimental Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany
    Clin Chem Lab Med 42:1377-83. 2004
    ..For human plasma we found a mean of 0.65 micromol/l in healthy subjects. In the plasma of mice and rats we found mean concentrations of 1.05 and 1.09 micromol/l, respectively...
  62. ncbi Antihypertensive therapy: special focus on drug interactions
    Renke Maas
    Institut fur Experimentelle und Klinische Pharmakologie, Universitätsklinikum HamburgEppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Expert Opin Drug Saf 2:549-79. 2003
    ..In this respect, the authors discuss controversial viewpoints on the overall clinical relevance of drug interactions occurring at the level of cytochrome P450 metabolism...
  63. ncbi Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma
    Edzard Schwedhelm
    Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Germany
    Clin Chem 51:1268-71. 2005
  64. ncbi Elevation of asymmetrical dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction
    Renke Maas
    Institut fur Experimentelle und Klinische Pharmakologie, Universitatsklinikum Hamburg Eppendorf, Germany
    Eur Urol 48:1004-11; discussion 1011-2. 2005
    ....
  65. ncbi Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients
    Ghainsom D Kom
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Br J Clin Pharmacol 63:672-9. 2007
    ..We investigated the effect of atorvastatin on PLA(2)s and PAF-AH activity and the urinary excretion of 15-F(2trans)-isoprostane (15-F(2t)-IsoP, 8-iso-PGF(2alpha), iPF(2alpha)-III)...
  66. ncbi High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma
    Edzard Schwedhelm
    Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 851:211-9. 2007
    ..37+/-0.07 microM in healthy humans (n=85), respectively, and 44+/-14, 0.72+/-0.23, and 0.19+/-0.06 microM in C57BL/6 mice. Also, the molar ratios of arginine to ADMA were different in man and mice, i.e. 166+/-50 and 85+/-22, respectively...
  67. ncbi Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study
    Friedrich Schulze
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Center of Experimental Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Am Heart J 152:493.e1-8. 2006
    ..It has been shown that ADMA predicts cardiovascular mortality in patients who have coronary heart disease (CHD). However, the question whether ADMA is an independent risk factor for CHD still remains unresolved...
  68. ncbi Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
    Ralf A Benndorf
    Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, D 20246 Hamburg, Germany
    Metabolism 55:1159-64. 2006
    ..Future studies will demonstrate whether these telmisartan-induced effects may contribute to a blood pressure-independent reduction in cardiovascular morbidity...
  69. ncbi Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia
    Renke Maas
    Clinical Pharmacology Unit, Institute for Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Atherosclerosis 191:211-9. 2007
    ..To investigate the association of the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) and coronary endothelial function...
  70. ncbi The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function
    Renke Maas
    Institut fur Experimentelle und Klinische Pharmakologie und Toxikologie, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Vasc Med 7:213-25. 2002
    ..Likewise, the role of endothelium-derived factors mediating NO-independent pathways is evaluated...
  71. ncbi Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial
    Georg Cachovan
    Department of Restorative and Preventive Dentistry, Center for Dental and Oral Medicine, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Antimicrob Agents Chemother 55:1142-7. 2011
    ..No significant differences between groups were found for patients with odontogenic abscesses...
  72. ncbi Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community
    Rainer H Boger
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Circulation 119:1592-600. 2009
    ..Although elevated ADMA has been associated with an increased risk of cardiovascular disease events and death in referral samples, the prognostic significance of ADMA in the community has not been adequately evaluated...
  73. ncbi Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke
    Frank Leypoldt
    Department of Neurology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    PLoS ONE 4:e7337. 2009
    ..ADMA is a predictor of cardiovascular events and mortality in humans. It is eliminated primarily by enzymatic activity of dimethylarginine dimethylaminohydrolase (DDAH)...
  74. ncbi Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension
    Renke Maas
    Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich Alexander University, Erlangen Nuremberg, Germany
    Pharmacol Res 60:488-93. 2009
    ..The mechanisms of this association need further investigation...
  75. ncbi Determination of NG,NG-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry
    Jennifer Albsmeier
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 809:59-65. 2004
    ..This method is fast, rugged and an alternative to high performance liquid chromatography (HPLC) analysis of ADMA in cell culture supernatants and small volumes of human plasma...
  76. ncbi Extensive characterization of the human DDAH1 transgenic mice
    Edzard Schwedhelm
    Institute of Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Pharmacol Res 60:494-502. 2009
    ....
  77. ncbi Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans
    R H Boger
    Institute of Clinical Pharmacology, Medical School, Hannover, Germany
    J Endocrinol Invest 22:75-81. 1999
    ..This hypothesis deserves further investigation in clinical trials...
  78. ncbi Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events
    Tanja K Krempl
    Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Eur Heart J 26:1846-51. 2005
    ..We investigated the role of asymmetric dimethylarginine (ADMA) for clinical outcome of patients with unstable angina...
  79. ncbi Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress
    Edzard Schwedhelm
    Institute of Experimental and Clinical Pharmacology, Clinical Pharmacology Unit, University Hospital of Hamburg Eppendorf, Hamburg, Germany
    Clin Pharmacokinet 42:437-59. 2003
    ..Catechins are degraded to several gamma-valerolactone derivatives and phase II conjugates have also been identified. Only limited clinical pharmacokinetic data for other polyphenols such as resveratrol have been reported to date...
  80. ncbi Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus
    Maike Anderssohn
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Diab Vasc Dis Res 7:105-18. 2010
    ..Anticipated advances in clinical and experimental investigation will help us to better understand this complex interrelationship between diabetes, eNOS, DDAH and ADMA...